Killion, Elizabeth A.
Amgen (United States)
4 papers on CoChatORCID 0000-0002-9321-3886
Most cited papers
- Verified
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine
Regulation of Appetite and ObesityPharmacology and Obesity Treatment
Cited by 237
- Verified
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications
Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases
Cited by 151
- Verified
Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists=antagonists?
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews
Regulation of Appetite and ObesityPharmacology and Obesity Treatment
Cited by 94
- Verified
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine
Regulation of Appetite and ObesityDiabetes Treatment and Management
Cited by 91
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free